Get to know Monotherapies better with 2 real example sentences, the meaning.
Monotherapies in a sentence
Monotherapies meaning
plural of monotherapy
Using Monotherapies
- The main meaning on this page is: plural of monotherapy
Context around Monotherapies
- Average sentence length in these examples: 24 words
- Position in the sentence: 1 start, 0 middle, 1 end
- Sentence types: 2 statements, 0 questions, 0 exclamations
Corpus analysis for Monotherapies
- In this selection, "monotherapies" usually appears near the start of the sentence. The average example has 24 words, and this corpus slice is mostly made up of statements.
- Around the word, artemisinin stand out and add context to how "monotherapies" is used.
- Recognizable usage signals include and as monotherapies and to artemisinin monotherapies in subtherapeutic. That gives this page its own corpus information beyond isolated example sentences.
- By corpus frequency, "monotherapies" sits close to words such as aabb, aabria and aacha, which helps place it inside the broader word index.
Example types with monotherapies
The same corpus examples are grouped by length and sentence type, making it easier to see the contexts in which the word appears:
Working together, the companies will develop Lynparza and selumetinib in combination with other potential new medicines and as monotherapies. (19 words)
Exposure of the parasite population to artemisinin monotherapies in subtherapeutic doses for over 30 years and the availability of substandard artemisinins likely drove the selection of the resistant phenotype. (29 words)
Exposure of the parasite population to artemisinin monotherapies in subtherapeutic doses for over 30 years and the availability of substandard artemisinins likely drove the selection of the resistant phenotype. (29 words)
Working together, the companies will develop Lynparza and selumetinib in combination with other potential new medicines and as monotherapies. (19 words)
Example sentences (2)
Working together, the companies will develop Lynparza and selumetinib in combination with other potential new medicines and as monotherapies.
Exposure of the parasite population to artemisinin monotherapies in subtherapeutic doses for over 30 years and the availability of substandard artemisinins likely drove the selection of the resistant phenotype.